Ownership history in Scientech Research LLC Β· 3 quarters on record
This page tracks every 13F SEC filing in which Scientech Research LLC reported a position in ULTRAGENYX PHARMACEUTICAL IN (RARE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Scientech Research LLC underperformed the S&P 500 by β103.2% annually on this RARE position. Average cost basis: $28.41. Maximum drawdown during holding period: β36.7%.
β Significantly underperformed the S&P 500 by 103.2% ann.
2 quarters analyzed
Best entry: $23.00 (2025 Q4) Β· Worst: $36.36 (2025 Q2)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
3 adds Β· 0 trims. Bought during 2 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Scientech Research LLC has been actively increasing its RARE allocation β a bullish signal from insiders.
Currently 0.69% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size